What’s new at SeqOne?
New platform features, customer success stories, awards and other great news about SeqOne…. you’ll find it all here. Journalists, we have a dedicated page for you.
-
Events News11 May 2023
SeqOne at ESHG 2023: A.I. for Diagnostics
We will be hosting a corporate satellite on Monday, June 12, 2023 – 14.00 – 15.30 BST : "Harnessing AI to improve diagnostic yield with [...]
-
News Press release
22 February 2023
SeqOne’s new clinically validated HRD test reduces the number of inconclusive results to improve the prescription of targeted treatments for ovarian cancer patients
The Homologous Recombination Deficiency (HRD) biomarker identifies ovarian cancer patients likely to respond to PARP inhibitors. SeqOne’s test simplifies the deployment of this test while [...]
-
News Platform features Press release Science
9 February 2023
SeqOne Genomics and the French Thrombotic MicroAngiopathies National reference center (CNR-MAT) pioneer the use of Oxford Nanopore sequencing technology to improve patient outcomes in kidney disease while reducing turnaround times
Montpellier, February 9th, 2023: SeqOne today announced the results of a long-standing research collaboration with Pr. Laurent Mesnard, Co-Director of the French National center for Thrombotic MicroAngiopathies (CNR-MAT), aimed at improving [...]
-
News Press release
21 October 2022
Michael Blum joins SeqOne Genomics to head the company’s Research and Development
Renowned specialist in healthcare data science, he will focus on developing A.I. driven genomic analysis solutions to facilitate personalised medicine in oncology and rare diseases [...]
-
Events News Press release
20 October 2022
SeqOne Genomics announces Portuguese distribution partnership
SeqOne has appointed ILC Instrumentos de Laboratório to distribute its genomic analysis software platform in Portugal, and to accelerate the availability of its advanced genomic [...]
-
News Press release18 May 2022
We are hiring a VP of Platform Sales
VP of Platform Sales: SeqOne is a well-funded company developing state-of-the-art genomic analysis tools for clinical applications in the fields of cancer and rare disease. The company's vision is [...]
-
Events News Press release
18 May 2022
SeqOne Genomics and Global Diagnostic Solutions Limited (GDS) extend their collaboration in MENA
The companies will participate at the Precision Med Expo Dubai 24th and 25th of May 2022 Montpellier, France – Dubai, May 18, 2022 - SeqOne Genomics, provider of [...]
-
Events News Publications6 May 2022
SeqOne posters at the ESHG: using ML and big data to improve variant interpretation
SeqOne will be at the ESHG show in Vienna in hall X4 booth 664. We will be presenting four posters high-lighting various projects by SeqOne's [...]
-
News Press release
4 February 2022
SeqOne Genomics – partenaire industriel du consortium FrOG (French OncoGenetics)
Pour le développement de FrOG, une base de données nationale centralisée et partagée, destinée à améliorer la prise en charge des patients en oncogénétique Paris, [...]
-
News Press release
4 February 2022
SeqOne Genomics selected as genomic analysis solution for CELIA (Comprehensive Genomic profiling impact) project, in collaboration with Illumina
The project aims to compare the clinical utility of broad-spectrum genomic profiling in the treatment of late-stage cancer patients with more traditional approaches that analyze [...]
-
News Press release
4 February 2022
SeqOne Genomics annonce son implication dans le projet « Célia » (Comprehensive Genomic profiling impact) aux côtés d’Illumina
• Ce projet vise à évaluer l’utilité clinique du profilage génomique complet (CGP) dans la prise en charge thérapeutique de patients atteints d’un cancer à [...]
-
News Press release
24 January 2022
SeqOne Genomics annonce un financement de 20 M€ en série A pour accélérer le déploiement de sa plateforme de médecine génomique
La Société va accélérer le déploiement mondial de sa plateforme d’analyse génomique de nouvelle génération afin de démocratiser la médecine personnalisée dans les cancers et [...]
